Adenovir Pharma AB
Anti-infectives for ophthalmic indications
This article was originally published in Start Up
Epidemic keratoconjunctivitis is a viral eye infection caused by a number of different adenoviruses. The highly contagious disease causes inflammation of the cornea and conjunctiva, leading to irritation, itching, discharge and pain in the eye, swelling of the eyelids, photophobia, and blurred vision. These vision problems can last for months or even years in infected individuals. Adenovir Pharma AB aims to improve treatment of EKC with a “molecular wipe” that captures the virus and prevents it from binding to the surface of the eye.
You may also be interested in...
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways
Redx Pharma PLC and its subsidiaries are focused on developing proprietary, small-molecule therapeutics to address areas of high unmet medical need principally in cancer, infection and autoimmune disease.